clobetasol and Choroid-Diseases

Bevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF). It is approved by the Food and Drug Administration (FDA) for metastatic colorectal cancer, advanced non-small cell lung cancer, metastatic renal cell cancer and glioblastoma. Bevacizumab has also been used off label in ophthalmology for age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and other chorioretinal vascular disorders. Numerous case reports have described various cutaneous reactions in response to bevacizumab therapy including acneiform eruptions and exfoliative dermatitis.. We report a case of a 63 year-old Caucasian female who presented with subacute cutaneous lupus erythematosus six weeks after initiating two intravitreal injections of bevacizumab for central serous choroidopathy.. We report the first documented case of a cutaneous lupus erythematosus eruption following bevacizumab administration as a monotherapy.

Topics: Administration, Topical; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroid Diseases; Clobetasol; Female; Humans; Injections; Keratosis; Lupus Erythematosus, Cutaneous; Middle Aged; Off-Label Use; Scalp; Skin; Vitreous Body